Influence of muramyl dipeptide on established experimental arthritis in rats

Autor: Jouzeau, J, Drelon, E, Gillet, G., Bannwarth, B, Fener, P., Charriere, G., Payan, E., Chauvelot-Moachon, L, Batt, A, Floquet, J.
Přispěvatelé: Laboratoire de Physiopathologie et Pharmacologie Articulaire (CNRS URA 1288), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Pharmacologie (URA CNRS 595 ), Centre du Médicament [Nancy], Université Henri Poincaré - Nancy 1 (UHP), Service d’Anatomie Pathologique [CHRU Nancy]
Jazyk: angličtina
Rok vydání: 1991
Předmět:
Zdroj: Agents and actions. Supplements
Agents and actions. Supplements, 1991, pp.191-5
ISSN: 0379-0363
Popis: International audience; The effects of MDP, a potent inducer of cytokines, were studied in four batches of Wistar Furth rats with established experimental arthritis. Arthritic rats were given a daily sc injection of 10, 100, 200 or 400 micrograms MDP respectively. Muramyl dipeptide increased the severity of clinical events in a dose-dependent manner, with the exception of the 10 micrograms dose which was ineffective. The levels of anti-collagen antibodies were not however significantly enhanced by MDP. Radiological lesions and histological changes were maximal at high dosage regimens. Paradoxically, the acute phase reactive alpha 1 glycoprotein was little affected by MDP treatment.
Databáze: OpenAIRE